Endios Bio, Inc.
Publicly observedBaton Rouge, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Baton Rouge | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Endios Bio, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | EUA8B6E2TJF5 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant18 Sept 2026Publicly observed
NIH SBIR/STTR award: Development of antisense oligonucleotides against PEG10 in the fight against ALS-FTD
USD 444,820.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.